Andrea Newkirk
Stock Analyst at Goldman Sachs
(0.53)
# 4,378
Out of 5,118 analysts
44
Total ratings
32%
Success rate
-9.6%
Average return
Main Sectors:
Stocks Rated by Andrea Newkirk
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterated: Buy | $188 → $194 | $114.41 | +69.57% | 8 | Oct 30, 2026 | |
| UTHR United Therapeutics | Reiterated: Sell | $321 → $368 | $562.02 | -34.52% | 2 | Oct 15, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Sell | $7 | $9.85 | -28.93% | 2 | Sep 30, 2026 | |
| KOD Kodiak Sciences | Reiterated: Hold | $103 | $99.30 | +3.73% | 2 | Sep 29, 2026 | |
| ABCL AbCellera Biologics | Initiated Coverage: Hold | $13 | $11.88 | +9.43% | 1 | Sep 24, 2026 | |
| ALKS Alkermes | Initiated Coverage: Hold | $26 → $50 | $45.90 | +8.93% | 2 | Sep 24, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Initiated Coverage: Hold | $85 → $74 | $58.16 | +27.24% | 3 | Sep 24, 2026 | |
| IOVA Iovance Biotherapeutics | Initiated Coverage: Buy | $2 → $15 | $8.04 | +86.57% | 4 | Sep 24, 2026 | |
| JAZZ Jazz Pharmaceuticals | Initiated Coverage: Buy | $154 → $337 | $234.76 | +43.55% | 2 | Sep 24, 2026 | |
| KRYS Krystal Biotech | Initiated Coverage: Buy | $194 → $441 | $300.88 | +46.57% | 3 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $540 → $704 | $399.63 | +76.16% | 3 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $16 | $9.00 | +77.78% | 1 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 → $267 | $192.28 | +38.86% | 2 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $68 → $116 | $68.60 | +69.10% | 4 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $19 → $21 | $29.82 | n/a | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.60 | n/a | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $19.88 | n/a | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.90 | n/a | 1 | Dec 4, 2024 |
Insmed
Oct 30, 2026
Reiterated: Buy
Price Target: $188 → $194
Current: $114.41
Upside: +69.57%
United Therapeutics
Oct 15, 2026
Reiterated: Sell
Price Target: $321 → $368
Current: $562.02
Upside: -34.52%
Sagimet Biosciences
Sep 30, 2026
Reiterated: Sell
Price Target: $7
Current: $9.85
Upside: -28.93%
Kodiak Sciences
Sep 29, 2026
Reiterated: Hold
Price Target: $103
Current: $99.30
Upside: +3.73%
AbCellera Biologics
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $13
Current: $11.88
Upside: +9.43%
Alkermes
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $26 → $50
Current: $45.90
Upside: +8.93%
Arrowhead Pharmaceuticals
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $85 → $74
Current: $58.16
Upside: +27.24%
Iovance Biotherapeutics
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $2 → $15
Current: $8.04
Upside: +86.57%
Jazz Pharmaceuticals
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $154 → $337
Current: $234.76
Upside: +43.55%
Krystal Biotech
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $194 → $441
Current: $300.88
Upside: +46.57%
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $540 → $704
Current: $399.63
Upside: +76.16%
Sep 24, 2026
Initiated Coverage: Hold
Price Target: $16
Current: $9.00
Upside: +77.78%
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $38 → $267
Current: $192.28
Upside: +38.86%
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $68 → $116
Current: $68.60
Upside: +69.10%
Nov 7, 2025
Reiterated: Hold
Price Target: $19 → $21
Current: $29.82
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $10.60
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $19.88
Upside: n/a
Dec 4, 2024
Rated: Hold
Price Target: n/a
Current: $3.90
Upside: n/a